Oncology News

A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.

A continuous risk score accurately predicted waitlist dropout and post-liver transplantation outcomes in patients with hepatocellular carcinoma, even over the course of several UNOS policy changes, researchers reported.

Hepatocellular carcinoma screening in at-risk patients was linked to reduced mortality after accounting for lead-time and length-time biases, as well as improved early tumor detection and treatment, according to data in JAMA Network Open.

Around 17% of patients with metabolic dysfunction-associated steatotic liver disease have or will be diagnosed with alcohol-related disease, which research shows is associated with a threefold higher rate of developing cirrhosis or cancer.

In a Healio video exclusive, Edward V. Loftus Jr., MD, urged gastroenterologists to familiarize themselves with a “four-pronged approach to liver disease” ahead of the critical shortage of U.S. hepatologists expected by 2033.

The role of gastroenterologists and hepatologists in the management of patients at risk for or with hepatocellular carcinoma is multifold.

Incidence of new portal vein thrombosis was higher after transarterial chemoembolization for hepatocellular carcinoma compared with microwave or radiofrequency ablation, although researchers reported no clinically significant sequalae.

Researchers found no association between Agent Orange exposure and hepatocellular carcinoma among Vietnam veterans, according to study results published in JAMA Network Open.

Asian patients with hepatocellular carcinoma had the lowest waitlist dropout rates and highest 5-year survival after liver transplantation before and after the policy change, while Black or African American patients had the worst outcomes.

Tenofovir disoproxil improved long-term overall and recurrence-free survival rates compared with entecavir among patients with hepatitis B virus-related hepatocellular carcinoma who underwent liver resection.